Acute ischemic stroke is a common cause of morbidity and mortality worldwide.
Thrombolysis with recombinant tissue plasminogen activator and endovascular …

Purpose—To critically review and evaluate the science behind individual eligibility criteria
(indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant …

Stroke syndromes present clinically as neurologic deficits of sudden onset. Symptoms
depend upon the affected region of brain, which in turn is defined by the arterial anatomy …

Background and Purpose—Recombinant tissue-type plasminogen activator (rtPA) is the
only approved therapy for acute ischemic stroke (AIS). In 2004, 1.8% to 2.1% of AIS patients …

Objective: To determine patient and hospital characteristics associated with not providing IV
tissue plasminogen activator (tPA) to eligible patients with acute ischemic stroke (AIS) in …

Stroke is a major contributor to death and disability worldwide. Prior to modern therapy, post-
stroke mortality was approximately 10% in the acute period, with nearly one-half of the …

Background—Substantial efforts over the past decade have increased rates of intravenous
tissue plasminogen activator (tPA) use in the United States. We sought to determine …

Background and Purpose—Little is known about intravenous recombinant tissue
plasminogen activator (rtPA) use in China. By accessing the Chinese National Stroke …

1994 and December 2003 to identify studies relevant to the treatment of stroke and the
establishment of stroke systems. A range of search terms* identified 1000 articles of …

Background: Stroke is a devastating condition encompassing a wide range of
pathophysiological entities that include thrombosis, hemorrhage, and embolism. Current …